Company Retains Command Consulting Group to Provide Support on Homeland Defense, Military, and Federal Government Procurement
WILMINGTON, MA, Jun 20, 2012 (MARKETWIRE via COMTEX) --Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a
high technology supplier of systems and sensors for homeland security
and defense markets, today announced that United States
Transportation and Security Administration (TSA) veteran Mo McGowan
has been retained as an advisor to the Company through a contract
with international security and intelligence consulting firm, Command
Consulting Group. Mr. McGowan will provide national security
expertise to advance Implant Sciences and its explosives and drugs
trace detectors in the United States market. He will focus on three
main segments -- military, homeland defense and security, and federal
government security screening.
Mr. McGowan spent seven years at the TSA and was recognized as one of
the founders of the organization. His career at the TSA culminated in
being appointed Assistant Administrator for the Office of Security
Operations, where he managed security operations. He was responsible
for the largest non-military workforce in the U.S. government, with
53,000 personnel. His operational responsibilities included the
screening of 2 million commercial air passengers per day and managing
a budget in excess of $3.7 billion. Mr. McGowan was instrumental in
transforming the culture and security posture of TSA's uniformed
workforce. While at TSA, he also served as Deputy Assistant
Administrator for Operations and General Manager for Cargo and Supply
Chain Security. Prior to his TSA experience, Mr. McGowan was a
Manager for the Systems Integrity Group of MCI and retired from the
command level with the Richardson, Texas Police Department. He is
currently a partner at Command Consulting Group.
Command Consulting Group works with a broad spectrum of clients to
develop customized products and services, understand the needs of
government and industry security consumers, and execute go-to-market
strategies in the United States and around the world. CCG's team of
operational security experts is comprised of professionals who
managed and led the organizations that make up much of the current
security architecture in the United States Government.
"Implant Sciences' products are an important part of the answer to
numerous security challenges facing the United States. The ability to
rapidly deploy systems in response to a security need provides
opportunities both in homeland security and for our troops abroad,"
stated Mo McGowan. "I'm looking forward to helping the Company get
its innovative technology into the hands of key frontline security
operators."
"Mo McGowan is one of the chief architects of the TSA. He's
intimately aware of the challenges the organization faces in securing
our borders and the technologies required to do the job. We are very
pleased to welcome him as an advisor," added Implant Sciences'
President and CEO, Glenn D. Bolduc.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated
sensors and systems for Security, Safety, and Defense (SS&D) markets.
The Company has developed proprietary technologies used in its
commercial explosive and narcotics trace detection systems which ship
to a growing number of locations domestically and internationally.
Implant Sciences' QS-H150 portable explosives trace detector has
received Qualified Anti-Terrorism Technology Designation and the
Company's QS-B220 desktop explosives and drugs trace detector has
received a Developmental Testing & Evaluation (DT&E) Designation by
the U.S. Department of Homeland Security under the Support
Anti-terrorism by Fostering Effective Technology Act of 2002 (the
SAFETY Act). For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain "forward-looking statements,"
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Such statements are based on management's current
expectations and are subject to risks and uncertainties that could
cause the Company's actual results to differ materially from the
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the risks that our explosives detection products
and technologies (including any new products we may develop) may not
be accepted by the Transportation Security Administration or by other
U.S. or foreign government and law enforcement agencies or commercial
consumers of security products; economic, political and other risks
associated with international sales and operations could adversely
affect our sales; our business is subject to intense competition and
rapid technological change; the risks that our markets are subject to
technological change and that our success depends on our ability to
develop and introduce new products; that our success depends on our
ability to obtain new patents and operate without infringing on the
proprietary rights of others; that we may not obtain the patents we
have applied for; that the validity and breadth of claims in
technology patents involve complex legal and factual questions and,
therefore, may be highly uncertain; that any patents we may obtain
may be may be challenged and subsequently invalidated, that we may
incur substantial costs in asserting our patent rights; and other
risks and uncertainties described in our filings with the Securities
and Exchange Commission, including its most recent Forms 10-K, 10-Q
and 8-K. Such statements are based on management's current
expectations and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
SOURCE: Implant Sciences Corporation
http://www2.marketwire.com/mw/emailprcntct?id=EB58CA7C4D0B7A25
http://www2.marketwire.com/mw/emailprcntct?id=D4B1F080A25792D2
